"In response to the need for mRNA COVID-19 vaccines during the pandemic ... and end-to-end RNA expertise under one roof, ...

Robert W. Baird analyst Brian Skorney maintained a Buy rating on Soleno Therapeutics (SLNO – Research Report) on November 6 and set a ...

In July 2024, Checkpoint announced that the FDA accepted for review the resubmission of its BLA for cosibelimab as a complete response to the complete response letter (“CRL”) issued in December 2023 ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus' versatile RNA therapeutics platforms can be applied toward ...

BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

About Checkpoint Therapeutics Checkpoint Therapeutics ... including the risk that the evolving and unpredictable Russia/Ukraine conflict and COVID-19 pandemic delay achievement of those milestones.

The study was conducted between 2021 and 2023, during the height of the COVID-19 global pandemic ... Prevention during the ...

(NASDAQ:MRNA) today announced it was ranked the number one large employer in BioSpace's 2025 Best Places to Work report based on the Company's reputation and commitment to innovation. 'We are honored ...

91% of treatment-related adverse events (TRAEs) were mild to moderate systemic reactions characteristic of mRNA-based therapeutics ... of mRNA vaccine candidates against influenza and COVID-19, ...